DOCUMENT RESOURCES FOR EVERYONE
Documents tagged
Business Fondapa Mon

1. Factor Xa Inhibition Across the Spectrum of ACS: A New Standard of Care Dr. Ihab Suliman 2. Meta-analysis of UFH and LMWH vs Placebo in UA/NSTEMI Eikelboom J.Lancet2000;355:1936–42…

Documents Paolo Trambaiolo UOSD di Terapia Intensiva Cardiologica Ospedale Sandro Pertini, Roma Il...

Slide 1 Paolo Trambaiolo UOSD di Terapia Intensiva Cardiologica Ospedale Sandro Pertini, Roma Il sanguinamento gastro-enterologico ed addominale Paolo Trambaiolo Seconda…

Health & Medicine Clots and Zealots

1. CLOTS AND ZEALOTS:A SCARY COMBINATION?“The only thing more dangerous than an ideais a belief.”Associate Professor David Mountain MB BS FACEMUniversity of Western Australia-…

Health & Medicine Lower gi bleed neo

1. Lower GI bleed Dr nawin kumar 2. • as any bleed that occurs distal to the ligament of Treitz and superior to the anus • 20-33% of episodes of gastrointestinal (GI)…

Documents Bambang Kegawatdaruratan Hemophilia

NILAI HAKIKI HEMOPHILIA EMERGENCY CARE IN HEMOPHILIA Bambang Sudarmanto Department of Child Health Medical Faculty Diponegoro University Kariadi Hospital Semarang 4/27/2013…

Documents Platelets and PlaNeT-2. Platelets and coagulation Damaged endothelium PLATELETS Adenosine...

Slide 1 Platelets and PlaNeT-2 Slide 2 Platelets and coagulation Damaged endothelium PLATELETS Adenosine diphosphate (calling effect) CollagenFibrinogen ↓ ↓ PLATELETS…

Documents Virginia ACP MSFM Session - Lipid Management & CVD Risk Reduction - Q1. What is the evidence that...

Slide 1 Virginia ACP MSFM Session - Lipid Management & CVD Risk Reduction - Q1. What is the evidence that adding a second pharmacologic agent to statin therapy improves…

Documents Should we??. Aspirin is useful! It is widely used in secondary prevention It reduces the yearly risk...

Slide 1 Should we?? Slide 2 Aspirin is useful! It is widely used in secondary prevention It reduces the yearly risk of vascular events by about a quarter This corresponds…

Documents ESC Congress 2008 Clinical Trial Summary Slides. 3T/2R Troponin I or T >3x ULN at 48 hours: 20% for....

ESC Congress 2008 Clinical Trial Summary Slides 3T/2R Troponin I or T >3x ULN at 48 hours: 20% for tirofiban vs. 35% for placebo (p = 0.009) MACE at 30 days: 21% vs. 37%…

Documents Data Monitoring for Safety apparent harm with a new treatment ILLUMINATE trial

* Evaluating Drug Safety in Clinical Trials (and Observational Registries) Stuart Pocock London School of Hygiene and Tropical Medicine * Issues in Drug Safety Data Monitoring…